Connect with us

AI Research

AI platform to accelerate medical research and more

Published

on


Health Tech World explores the latest business and pharmaceutical developments in the world of health technology.

AI platform to accelerate medical and epidemiological research

Health technology company Briya has announced the launch of Briya AIRE, the world’s first clinical-grade AI research assistant built to accelerate biomedical and clinical decision making.

Designed to “think” in the language of medicine, clinical research and epidemiology, AIRE turns months of manual data analysis into actionable insights in minutes to enable faster, cost-effective discovery across biopharma and academic research sectors.

Incorporating Briya AIRE into research and clinical practice has the potential to revolutionise medical care,” said Robert Brown, Vincent Astor distinguished professor of medicine at Weill Cornell Medicine.

Using AI to collate patient data and clinical evidence will allow physicians to make better decisions in a more efficient and timely manner while reducing administrative burden so they can spend more time interacting with and thinking about their patients.

Briya AIRE acts as a virtual epidemiologist and data analyst, helping researchers ask better questions and generate answers faster.

It is built to design patient cohorts, test hypotheses, refine study criteria, and identify data patterns otherwise missed.

By guiding researchers through these critical steps, it also helps optimise study design and accelerate discoveries that can impact drug development and patient care.

“Using the advanced NLP capabilities, we can now accurately identify patients with metabolic dysfunction-associated steatohepatitis (MASH) at significant risk of progressing to severe liver damage or cirrhosis, directly from unstructured clinical data across the healthcare ecosystem,” said Gadi Lalazar, head of the Liver Unit, Shaare Zedek Medical Center.

This ability to automatically analyse imaging reports opens the door to earlier interventions for these high-risk patients, and spells promise for its use in a wide range of indications.

Omni Health Ring launches EnerQi following US$300k kickstarter fundraise

Health technology company Omni Health has launched a new health metric called EnerQi for the Omni Health Ring smart wearable.

Omni Health Ring generates an AI-powered daily plan that works across food, movement, and rest. The plan is personalised to the wearer’s body signals.

The new health metric EnerQi is a comprehensive health index that includes sleep, exercise, stress, nutrition, and provides real-time updates based on the wearer’s behaviour.

The public launch on the company’s official website follows a successful Kickstarter campaign this past April, which raised over $300,000 from early adopters.

Hatteras Venture Partners raises over US$200m

Hatteras Venture Partners has announced the final closings of Hatteras Venture Partners VII (HVP VII) and Hatteras Opportunity Fund I with over US$200m in capital commitments from limited partners.

The fund closings come at a time as Hatteras has invested in its 100th portfolio company.

Hatteras began in 2000 with the closing of Hatteras Venture Partners I, LP, a seed-stage venture fund with US$2.93m in capital.

Today, the firm manages over US$900m in capital focused on seed- and early-stage companies in the health innovation sectors of biotechnology, medtech, and healthtech.

In addition to building the Hatteras capital base, the firm has made two important promotions within its team. Ben Scruggs has been promoted from principal to partner with a focus on biopharmaceuticals and tools investments.

Lauren Flickinger has also been promoted from principal to partner. Lauren joined Hatteras in 2021 from Morgan Stanley, where she was an investment banker.

Philips plans for US$150m for AI-powered health technology Innovations

Global tech giant Philips is planning new investments of more than US$150m in US manufacturing and research and development (R&D).

As part of the announcement, Philips has unveiled the expansion of its Reedsville, PA, manufacturing facility, which produces AI-enabled ultrasound systems for hospitals across the US.

These investments come on top of Philips’ annual US$900m R&D investment in the US as well as investments in nearly 17,000 colleagues across 40 facilities in the United States.

The investment includes the expansion of its Reedsville, PA, site and the recently announced expansion of Philips’ Image Guided Therapy facility in Plymouth, MN.

It also includes additional manufacturing and R&D projects which will come over the next several years to support the company’s growth in the US.

The Reedsville site, which currently manufactures transducers, will also customise the software and configurations of ultrasound systems for specific clinical procedures in cardiovascular, general and maternal care following the expansion.

As an example, Philips’ industry-leading CV ultrasound platform delivers advanced tools to help doctors diagnose structural heart and coronary artery disease.

The expansion of the Reedsville site is expected to add 24,000 square feet of manufacturing space in addition to 40,000 square feet of warehouse space and is expected to create 120 skilled manufacturing jobs.

The recently announced expansion of Philips’ image-guided therapy facility in Plymouth, MN, which includes the construction of a new medtech training center, is expected to create over 150 new jobs.

Collaboration to improve outcomes for patients with diabetes and chronic conditions

Humana and health technology pioneer DrFirst has announced the launch of a programme designed to close gaps in care for patients with chronic health conditions like diabetes and cardiovascular disease. The programme also aims to help health care providers take timely, informed action.

The first phase of the programme aims to increase the use of statin therapy among eligible patients, aligning with a key quality metric from the Centers for Medicare & Medicaid Services (CMS).

The use of statins for certain Medicare patients is associated with lower cardiovascular risk, better outcomes and reduced health care costs.

To address this, Humana is partnering with DrFirst to connect with prescribers within the clinical workflow.

Using the DrFirst prescription orchestration platform, Humana can now initiate new prescription recommendations for these high-risk patients and submit them to the health care provider for consideration. Providers can approve the prescription recommendation and generate a new prescription or note why it is not an appropriate choice for the patient.

“This partnership is about more than innovative technology; it’s about better patient outcomes,” said Laizer Kornwasser, DrFirst CEO.

“As a company dedicated to taking the friction out of health care, it’s especially meaningful to introduce an entirely new approach to medication management.”

Because DrFirst e-prescribing technology is used in over 270 EHRs, the prescription orchestration platform can be quickly implemented in workflow across care settings.

The collaboration builds on a decade-long track record of innovation between Humana and DrFirst.

In 2015, the companies partnered to introduce the first real-time prescription benefit tool, enabling providers to view patient-specific coverage, costs and prior authorisation requirements at the point of prescribing.





Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

AI Research

The Big Idea: why we should embrace AI doctors | Books

Published

on


We expect our doctors to be demi-gods – flawless, tireless, always right. But they are only human. Increasingly, they are stretched thin, working long hours, under immense pressure, and often with limited resources. Of course, better conditions would help, including more staff and improved systems. But even in the best-funded clinics with the most committed professionals, standards can still fall short; doctors, like the rest of us, are working with stone age minds. Despite years of training, human brains are not optimally equipped for the pace, pressure, and complexity of modern healthcare.

Given that patient care is medicine’s core purpose, the question is who, or what, is best placed to deliver it? AI may still spark suspicion, but research increasingly shows how it could help fix some of the most persistent problems and overlooked failures – from misdiagnosis and error to unequal access to care.

As patients, each of us will face at least one diagnostic error in our lifetimes. In England, conservative estimates suggest that about 5% of primary care visits result in a failure to properly diagnose, putting millions of patients in danger. In the US, diagnostic errors cause death or permanent injury to almost 800,000 people annually. Misdiagnosis is a greater risk if you’re among the one in 10 people worldwide with a rare disease.

Modern medicine prides itself on being scientific, yet doctors don’t always practise what the evidence recommends. Studies show that evidence-based treatments are offered only about half the time to adults in the US. Doctors can also disagree about diagnoses. In a study of more than 12,000 radiology images, reviewers offering second opinions disagreed with the original assessment in about one in three cases – leading to a change in treatment nearly 20% of the time. As the work day wears on, quality slips further: inappropriate antibiotic prescriptions rise, while cancer screening rates fall.

As alarming as this is, there are understandable reasons for these failures – and viewed from another angle, it’s remarkable that doctors get it right as often as they do. The realities of being human – distraction, multitasking, even our body clocks – take a toll. But burnout, depression and cognitive ageing don’t just wear doctors down; they raise the risk of clinical mistakes.

Medical knowledge also moves faster than doctors can keep up. By graduation, half of what medical students learn is already outdated. It takes an average of 17 years for research to reach clinical practice, and with a new biomedical article published every 39 seconds, even skimming the abstracts would take about 22 hours a day. There are more than 7,000 rare diseases, with 250 more identified each year.

In contrast, AI devours medical data at lightning speed, 24/7, with no sleep and no bathroom breaks. Where doctors vary in unwanted ways, AI is consistent. And while these tools make errors too, it would be churlish to deny how impressive the latest models are, with some studies showing they vastly outperform human doctors in clinical reasoning, including for complex medical conditions.

AI’s superpower is spotting patterns humans miss, and these tools are surprisingly good at recognising rare diseases – often better than doctors. For example, in one 2023 study researchers fed 50 clinical cases – including 10 rare conditions – into ChatGPT-4. It was asked to provide diagnoses in the form of ranked suggestions. It solved all of the common cases by the second suggestion, and got 90% of the rare conditions by the eighth – outperforming the human doctors used as comparators. Patients and their families are increasingly recognising these benefits. One child, Alex, saw 17 doctors over three years for chronic pain – none could explain his symptoms. Desperate, his mother turned to ChatGPT, which suggested a rare condition called tethered cord syndrome. Doctors confirmed the diagnosis, and Alex is now receiving proper treatment.

Then there’s the problem of access. Healthcare is upside down. Those most in need – the sickest, poorest, and most marginalised in society – are the ones most likely to be left behind. Packed schedules and poor public transport mean millions miss appointments. Parents and part-time workers, including those with gig economy jobs, often struggle to attend checkups. American Time Use Survey data shows patients sacrifice two hours for a 20-minute doctor’s visit. The problems are often worse for people with disabilities, who are about four times more likely to miss out on care in the UK due to issues with transport, costs and long waiting lists. Compared with men with no disability, disabled women are more than seven times more likely to have unmet needs due to the cost of care or medication.

And yet we rarely question the idea of waiting in line at the doctor’s office in town because it’s simply the way things have always been done. AI could change that. Imagine a doctor in your pocket offering information when and where you need it. Under Labour’s 10-year plan, Wes Streeting, the health secretary, has announced that patients will soon be able to discuss their health concerns with AI via the NHS app. It’s a bold step – and one that could bring quicker, actionable clinical advice for millions.

This will only work for those who can use it, of course. Internet access is improving globally, but there are still serious gaps: 2.5 billion people remain offline. In the UK, 8.5 million people lack basic digital skills, and 3.7 million families fall below the “minimum digital living standard”, meaning they have poor connectivity, outdated devices and limited support. Confidence is a barrier too: 21% of people in the UK say they feel left behind by technology.

At the moment, AI healthcare research almost exclusively fixates on its flaws. Examining the technology’s potential for bias and errors is a crucially important task. But this orientation doesn’t take account of the creaking and sometimes unsafe systems we already rely on. Any fair assessment of AI must be weighed against the realities of what we’ve currently got – a system that too often can be frustrating, out of reach, or just plain wrong.

Charlotte Blease is a health researcher and the author of Dr Bot: Why Doctors Can Fail Us – and How AI Could Save Lives, published by Yale on 9 September.

Further reading

Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again by Eric Topol (Basic Books, £28)

Co-Intelligence: Living and Working with AI by Ethan Mollick (WH Allen, £16.99)

Artificial Intelligence: A Guide for Thinking Humans by Melanie Mitchell (Pelican, £10.99)



Source link

Continue Reading

AI Research

Billionaire Philipe Laffont Just Sold Coatue Management’s Stake in Super Micro Computer and Piled Into Another Artificial Intelligence (AI) Giant Up Over 336,000% Since Its IPO

Published

on


Philipe Laffont is part of an elite group of investors called the Tiger Cubs, who worked for Julian Robertson’s Tiger Management in the 1990s.

In the 1990s, an elite group of investors worked for a tech-focused hedge fund called Tiger Management, led by the legendary investor Julian Robertson. Not only did Robertson mentor this group of investors, but he would go on to seed many of their future hedge funds as the talented group, referred to as the Tiger Cubs, went on to become great investors in their own right.

Philippe Laffont, the founder of Coatue Management, is part of this group, and is now viewed as one of the great tech investors of the modern era. Coatue Management’s equity holdings were valued at roughly $35 billion at the end of the second quarter. That’s why investors are always paying attention to which stocks Coatue is buying and selling.

In the second quarter, the fund sold its stake in Super Micro Computer (SMCI -5.42%) and piled into another artificial intelligence (AI) giant that generated a total return over 336,000% since its initial public offering.

Image source: Getty Images.

Super Micro Computer: Beating the shorts so far

AI and tech infrastructure and server maker Super Micro Computer has been a controversial and volatile play for the past year. In August 2024, short-seller Hindenburg Research came out with a major short report alleging potential accounting fraud at the company. The report said that Supermicro rehired executives who had been a part of an accounting scandal at the company in 2018 that involved understating expenses and overstating revenue.

The stock got hit hard after Supermicro announced it would need to delay its annual 2024 filing to assess its internal controls. However, the company would eventually go on to file its 2024 10-K and did not need to restate any of its financial statements, a good sign for investors. Furthermore, management earlier this year also provided strong fiscal 2026 guidance of $40 billion in revenue, way ahead of consensus at the time. Supermicro’s fiscal year ends on June 30 of each year.

In August, shares struggled after the company reported lower-than-expected quarterly results and weaker-than-expected guidance, due to President Donald Trump’s tariffs, which resulted in less working capital in June and “specification changes from a major new customer.” Laffont and Coatue loaded up on the stock some time in the fourth quarter of 2024 and sold in the second quarter of this year, so the fund could have bought the dip after the short report and might have sold over concerns about tariffs, although that’s speculation. Supermicro’s stock is up about 46% this year, so Coatue seems to have timed its trade well.

Supermicro looks real cheap right now for a stock benefiting from the AI boom, trading around 16 times forward earnings. Tariffs are likely to be an ongoing issue but if AI demand remains strong, Supermicro, which supplies servers to the likes of Nvidia, should be a major beneficiary. The stock may remain volatile, but I think investors can take a position in the more speculative part of their portfolio.

Oracle: A longtime tech player benefiting from AI

With a market cap of nearly $664 billion, Oracle (ORCL -5.97%) isn’t part of the “Magnificent Seven,” but it’s another large tech company expected to benefit from the AI capital expenditure boom. Coatue purchased over 3.8 million shares in the second quarter, valued at over $843 million.

The cloud giant offers clients the ability to tap into a number of AI solutions including generative AI and machine learning capabilities that provide automation tools and AI application development, among other services. Similar to Microsoft and Amazon, although not as dominant, Oracle’s position as a cloud provider positions the company well to be a first point of contact for clients looking to add AI capabilities.

In the company’s most recent earnings report for its fourth quarter of fiscal 2025, which ended May 31, Oracle reported results ahead of Wall Street estimates and said that cloud infrastructure revenue sales should increase 70% in fiscal year 2026, after generating 52% growth in fiscal 2025.

Oracle CEO Larry Ellison said the company is particularly well positioned because it has a strong data advantage and has developed one of the most comprehensive databases in the world. “Our applications take all of your application data and make that data available to the most popular AI models,” he said on Oracle’s earnings call for the company’s fiscal fourth quarter of 2025.

If you like ChatGPT, you use ChatGPT. If you like Grok, you use Grok. You use that in the Oracle Cloud. We are the key enabler for enterprises to use their own data and models. No one else is doing that.

Having gone public in 1986, Oracle has been a major tech disruptor for decades. The stock is up over 336,000% since its initial public offering and also up over 41% this year. Trading at 34 times forward earnings, the stock is not necessarily cheap, but given its track record and strong expected growth in cloud infrastructure, Oracle can benefit from AI without being as much in the spotlight as some of the Magnificent Seven names.

Bram Berkowitz has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, Microsoft, Nvidia, and Oracle. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.



Source link

Continue Reading

AI Research

TikTok Salaries Revealed: How Much AI, E-Commerce Workers Make in 2025

Published

on


TikTok’s US plans are up in the air due to a divest-or-ban law that puts its future in jeopardy. But it’s still offering six-figure salaries to workers this year in key areas like e-commerce and artificial intelligence.

It’s sought to hire data scientists to sharpen its search algorithm, court workers to grow its e-commerce platform TikTok Shop, and bring in machine learning engineers to improve its content feed and recommendations.

The company’s jobs portal lists over 1,800 open roles in the US in cities like Austin, San Jose, Seattle, and New York.

Like other Big Tech firms, work expectations at TikTok and its owner, ByteDance, are demanding. The company runs performance reviews twice a year, and low scorers can be placed on performance-improvement plans or even shown the door. But the opportunity to work at one of the most influential tech companies in the world continues to draw in talent.

Outside e-commerce, TikTok is shaking up areas like music marketing and young people’s news habits. If it can navigate political tides in the US and China, where ByteDance was founded, it will stand alongside YouTube and a few other players in shaping the next phase of media.

“From a career growth standpoint, you have access to huge budgets and big names,” a former staffer said of working at TikTok. “Everyone in the industry wants to talk to you.”

While TikTok and ByteDance don’t disclose salary information publicly (unless required by state law), they do submit pay ranges in federal filings when they look to hire workers from outside the US.

To understand more about the company’s pay rates, Business Insider reviewed thousands of TikTok salary offers for foreign hires at the company, as well as its owner, ByteDance, for the first three quarters of this reporting year that ran through June 30. The results don’t include equity or other benefits that employees often receive in addition to base pay. But they paint a picture of the range of pay a worker might expect in roles like software engineering, data science, or product management.

The foreign-hire data shows a wide range of salaries at the companies. For example, a finance representative could earn $65,000 a year, and a global head of product and design position could fetch a $949,349 annual salary.

Backend software engineers at TikTok could earn between $144,000 and $301,158, based on the salary data, though rates increased beyond that for specialties like trust and safety. Data scientist positions at TikTok were generally offered between $85,821 and $283,629 — or more in specific areas like e-commerce. For TikTok machine learning scientists, the range was between $168,000 and $390,000, while general marketing managers were offered between $85,000 and $430,000.

These salary offers fall in line with pay rates in federal applications at other Big Tech firms. Meta’s first-quarter visa filings revealed it offered data scientists between $122,760 and $270,000, for example. Meanwhile, a staff software engineer at Google could receive between $220,000 and $323,000, according to the company’s first-quarter filings.

Here are the salary ranges TikTok and ByteDance offered for other roles in key business areas, based on recent applications. TikTok and ByteDance did not respond to requests for comment.

E-commerce and TikTok Shop roles

TikTok Shop – Celebrity Team Live Operation Manager: $94,000

TikTok Shop – US Data Analyst – Logistics: $128,000

TikTok Shop – Campaign Strategy Operations Manager: $132,000

TikTok Shop – Category Manager – Health: $135,000

TikTok Shop – Anti-Fraud Ops Program Mgr – Global Selling: $180,000

TikTok Shop – Data Scientist: $218,000 to $304,000

Product Manager, User Growth Customer Lifecycle-TikTok Shop: $220,000

Strategy Manager, E-Commerce: $228,000 to $230,000

Software Engineer – E-commerce Recommendation Infrastructure: $237,000 to $315,207

TikTok Shop – Inventory Placement Strategy Manager: $250,000

TikTok Shop- Compliance Operation: $257,600

Senior Machine Learning Engineer, E-commerce: $320,000

Tech Lead – E-commerce Recommendation Infrastructure: $320,113

Logistics Procurement Lead, TikTok US E-commerce: $350,000

Senior Data Scientist, Content E-commerce: $350,000

Tech Lead, Global E-commerce Governance Platform: $365,000

Global E-commerce Solutions Manager: $480,000

AI and machine learning roles

Software Engineer (AI Platform): $144,000

Research Scientist (TikTok AI Privacy): $188,000

Product Manager GenAI Safety, Trust & Safety: $218,400

Senior Product Designer, Creation (AI Projects): $221,368

Machine Learning Engineer – Computer Vision: $228,960

Software Engineer, Machine Learning Infrastructure: $270,000 to $320,783

Site Reliability Engineer, AI Applications: $276,000

AI Product Manager: $300,010

Product Manager Lead, Emerging Product & AI Safety: $336,000

AI Security Researcher – Security Flow: $340,000

Senior Machine Learning Engineer, TikTok Recommendation: $386,115

Search roles

Search Product Operations – Creator Search Optimization: $110,000

Software Engineer – TikTok Search Business Infrastructure: $154,880 to $214,720

Product Manager, Search Ads: $205,000

Machine Learning Engineer – Search Ads: $229,200 to $354,000

Machine Learning Engineer – TikTok Search: $241,200 to $300,000

Senior Machine Learning Engineer – TikTok Search Business: $268,920

Product Manager – TikTok Search: $287,500

Product Manager, Search Content Ecosystem: $400,000

Leader of Search and Recommendation Product (ByteDance): $540,552

Search Ads Closed-loop Product Manager: $564,000





Source link

Continue Reading

Trending